R
Radical Numerics
AI-powered scientific world models for complex systems.
About Radical Numerics
Radical Numerics is a research-focused company developing next-generation artificial intelligence for scientific applications. Based in Menlo Park, California, and founded in 2025, the startup spun out of Stanford University with the mission to build AI that can design and improve itself. The company was co-founded by Michael Poli (CEO), Stefano Massaroli, Eric Nguyen, and a fourth unnamed founder. Poli, a Stanford PhD, and Massaroli knew each other from their hometown in Italy, while Nguyen was also a PhD candidate at Stanford. The founding team includes researchers from institutions like DeepMind, Meta, and Liquid AI.
Read full description
Radical Numerics operates at the intersection of AI and life sciences, building multimodal models trained on biological data to accelerate discovery. The team is noted for its work on Evo and Evo 2, generative genomics models used to create gene-editing tools and the first AI-designed whole genomes. This technology demonstrated that AI can be used to create new biology, not just analyze it. Their work on a model named Evo, which was trained on DNA sequences to design a novel CRISPR-Cas system, was featured on the cover of Science magazine. Another creation from their models was a phage, a type of virus that only attacks bacteria, illustrating the technology's potential as an antibiotic.
The company develops foundational architectures and numerical computing frameworks to represent complex physical systems, such as in climate modeling, materials discovery, and robotics, as learnable world models. They focus on creating AI systems specifically for science, arguing that architectures designed for language are not suited for understanding DNA or physical systems. Radical Numerics has released open-source models, including RND1-Base, a 30-billion parameter diffusion language model, to encourage further research in the community. By concentrating on systems and architecture innovations, the firm aims to enable AI to autonomously design AI, thereby speeding up scientific and industrial advancements.
At a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- San Francisco, United States
- Employees
- 16
- Open positions
- 11
- Dealroom signal
- 60.2/100
- Industry
- Health
- Sector
- Health, Drug Development, Genetics and genomics, Generative AI
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Radical Numerics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Jun 2026 | $50M | $200M | Patrick Collison · Obvious Ventures · Factory · First Spark Ventures | ↗ |
Growth signals
Latest recorded traffic for Radical Numerics is 19K monthly website visits, up 493.8% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
DataInformation TechnologyAI-powered drug discovery and clinical validation platform. |
China | Operational | — | $2.8M | $28M |
Proxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation |
New York City, United States | Operational | |||
LabNinjaAI automation for targeted, replication-ready experimental data |
— | Operational | |||
SilicoScientiaAI-powered computational platform for drug discovery. |
India | Operational | |||
GalagosAI-powered bioinformatics platform for complex biological data. |
Hamburg, Germany | Operational | |||
Pattern AgentixAI-native bioscience platform for accelerating scientific discovery. |
Canada | Operational | |||
EpsilicoGenerative AI for protein therapy design |
Berlin, Germany | Operational | |||
Cambridge Precision Dosing Inc.Predictive modeling for personalized patient drug dosing. |
Cambridge, United States | Operational |
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Emergence
Patrick Collison
Obvious Ventures
Factory
First Spark Ventures
Triatomic Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Radical Numerics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Radical Numerics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







